Xeris Biopharma (NASDAQ:XERS) Downgraded by Wall Street Zen to Hold
Wall Street Zen downgraded shares of Xeris Biopharma (NASDAQ:XERS – Free Report) from a buy rating to a hold rating in a research note published on Thursday morning. A number of other research firms also recently weighed in on XERS. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave […]
Wall Street Zen downgraded shares of Xeris Biopharma (NASDAQ:XERS – Free Report) from a buy rating to a hold rating in a research note published on Thursday morning. A number of other research firms also recently weighed in on XERS. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave […]
